FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.8.4  |  FHIR Version n/a  User: [n/a]

1495581000168106: List of Medicines for Brand Consideration reference set (foundation metadata concept)


Status: current, Primitive. Date: 30-Sep 2020. Module: Third party reference set module

Descriptions:

Id Description Lang Type Status Case? Module
4462321000168116 List of Medicines for Brand Consideration reference set (foundation metadata concept) en Fully specified name Active Initial character case insensitive Third party reference set module
4462331000168118 List of Medicines for Brand Consideration reference set en Synonym Active Initial character case insensitive Third party reference set module
4462411000168119 List of Medicines for Brand Consideration (LMBC) reference set en Synonym Active Initial character case insensitive Third party reference set module
4462641000168118 <p>Supports the identification of AMT Medicinal Product Unit of Use (MPUU) and Medicinal Product Pack (MPP) concepts associated with the List of Medicines for Brand Consideration (LMBC) that forms part of the Active Ingredient Prescribing initiative. Under the <i>National Health (Pharmaceutical Benefits) Regulations 2017</i>, the <i>Repatriation Pharmaceutical Benefits Scheme Instrument 2013</i> and <i>MRCA Pharmaceutical Benefits Scheme Instrument 2013</i>, all PBS and RPBS prescriptions must be prepared by active ingredient, the brand may additionally be identified if a prescriber considers it necessary. The LMBC supports prescribers' decision-making regarding the inclusion of brand on a prescription.</p><p>This reference set can be used by prescribing software vendors to identify medications for brand consideration to meet Active Ingredient Prescribing requirements.</p><p><b>Target Client:&nbsp;</b>This reference set was developed by the National Clinical Terminology Service for the Australian Government Department of Health and Aged Care to support the Active Ingredient Prescribing initiative, and can be used by developers to assist with the requirements.</p> en Definition Active Case sensitive Third party reference set module


1324 members. Search Members:

Expanded Value Set


Outbound Relationships Type Target Active Characteristic Refinability Group Values
List of Medicines for Brand Consideration reference set Is a Reference sets for Medications true Inferred relationship Some
List of Medicines for Brand Consideration reference set Is a Simple type reference set true Inferred relationship Some
List of Medicines for Brand Consideration reference set Developed by Australian Government Department of Health and Aged Care true Inferred relationship Some 1570063879

Members
mesalazine 500 mg modified release granules, 100 sachets
mesalazine 500 mg modified release granules, 300 sachets
mesalazine 500 mg modified release granules, 50 sachets
mesalazine 500 mg modified release granules, sachet
mesalazine 500 mg modified release tablet
mesalazine 500 mg modified release tablet, 100
mesalazine 500 mg modified release tablet, 30
mesalazine 800 mg enteric tablet
mesalazine 800 mg enteric tablet, 180
mesalazine 800 mg enteric tablet, 30
mesalazine 800 mg enteric tablet, 60
mesalazine 800 mg enteric tablet, 90
norethisterone 1 mg + mestranol 50 microgram tablet
norethisterone 1 mg + mestranol 50 microgram tablet, 21
norethisterone 1 mg + mestranol 50 microgram tablet, 4 x 21
methylprednisolone 40 mg injection, chamber
methylprednisolone 40 mg injection, vial
methylprednisolone 40 mg injection, 5 vials
methylprednisolone aceponate 0.1% ointment
methylprednisolone aceponate 0.1% ointment, 10 g
methylprednisolone aceponate 0.1% ointment, 100 g
methylprednisolone aceponate 0.1% ointment, 15 g
methylprednisolone aceponate 0.1% ointment, 30 g
methylprednisolone aceponate 0.1% ointment, 5 g
methylprednisolone aceponate 0.1% ointment, 50 g
methylprednisolone acetate 40 mg/mL modified release injection, vial
methylprednisolone acetate 40 mg/mL modified release injection, 1 mL vial
methylprednisolone acetate 40 mg/mL modified release injection, 5 x 1 mL vials
mifepristone 200 mg tablet [1] (&) misoprostol 200 microgram tablet [4], 1 pack
misoprostol 200 microgram tablet
misoprostol 200 microgram tablet, 120
misoprostol 200 microgram tablet, 4
morphine hydrochloride trihydrate 10 mg/mL injection, ampoule
morphine hydrochloride trihydrate 10 mg / 1 mL injection, 10 x 1 mL ampoules (medicinal product pack)
morphine hydrochloride trihydrate 10 mg/mL injection, 5 x 1 mL ampoules
morphine sulfate pentahydrate 10 mg/mL injection, ampoule
morphine sulfate pentahydrate 10 mg/mL injection, 10 x 1 mL ampoules
morphine sulfate pentahydrate 10 mg/mL injection, 5 x 1 mL ampoules
morphine sulfate pentahydrate 10 mg/mL injection, 50 x 1 mL ampoules
morphine sulfate pentahydrate 10 mg modified release capsule
morphine sulfate pentahydrate 10 mg modified release capsule, 20
morphine sulfate pentahydrate 10 mg modified release capsule, 28
morphine sulfate pentahydrate 10 mg modified release capsule, 60
morphine sulfate pentahydrate 10 mg modified release tablet
morphine sulfate pentahydrate 10 mg modified release tablet, 20
morphine sulfate pentahydrate 10 mg modified release tablet, 28
morphine sulfate pentahydrate 10 mg modified release tablet, 60
morphine sulfate pentahydrate 10 mg tablet
morphine sulfate pentahydrate 10 mg tablet, 20
morphine sulfate pentahydrate 10 mg tablet, 56
morphine sulfate pentahydrate 20 mg modified release capsule
morphine sulfate pentahydrate 20 mg modified release capsule, 20
morphine sulfate pentahydrate 20 mg modified release capsule, 28
morphine sulfate pentahydrate 20 mg modified release capsule, 60
morphine sulfate pentahydrate 20 mg tablet
morphine sulfate pentahydrate 20 mg tablet, 20
morphine sulfate pentahydrate 20 mg tablet, 56
morphine sulfate pentahydrate 30 mg modified release capsule
morphine sulfate pentahydrate 30 mg modified release capsule, 10
morphine sulfate pentahydrate 30 mg modified release capsule, 14
morphine sulfate pentahydrate 30 mg modified release tablet
morphine sulfate pentahydrate 30 mg modified release tablet, 20
morphine sulfate pentahydrate 30 mg modified release tablet, 28
morphine sulfate pentahydrate 30 mg modified release tablet, 60
morphine sulfate pentahydrate 30 mg tablet
morphine sulfate pentahydrate 30 mg tablet, 10
morphine sulfate pentahydrate 30 mg tablet, 20
morphine sulfate pentahydrate 30 mg tablet, 6
morphine sulfate pentahydrate 30 mg tablet, 8
mycophenolate 180 mg enteric tablet
mycophenolate 180 mg enteric tablet, 120
mycophenolate 360 mg enteric tablet
mycophenolate 360 mg enteric tablet, 120
mycophenolate mofetil 250 mg capsule
mycophenolate mofetil 250 mg capsule, 100
mycophenolate mofetil 250 mg capsule, 300
mycophenolate mofetil 250 mg capsule, 50
mycophenolate mofetil 250 mg capsule, 500
mycophenolate mofetil 500 mg tablet
mycophenolate mofetil 500 mg tablet, 10
mycophenolate mofetil 500 mg tablet, 100
mycophenolate mofetil 500 mg tablet, 150
mycophenolate mofetil 500 mg tablet, 30
mycophenolate mofetil 500 mg tablet, 300
mycophenolate mofetil 500 mg tablet, 50
mycophenolate mofetil 500 mg tablet, 500
norethisterone 350 microgram tablet
norethisterone 350 microgram tablet, 28
norethisterone 350 microgram tablet, 4 x 28
oxycodone hydrochloride 10 mg capsule
oxycodone hydrochloride 10 mg capsule, 10
oxycodone hydrochloride 10 mg capsule, 20
oxycodone hydrochloride 10 mg capsule, 60
oxycodone hydrochloride 10 mg modified release tablet
oxycodone hydrochloride 10 mg modified release tablet, 10
oxycodone hydrochloride 10 mg modified release tablet, 100
oxycodone hydrochloride 10 mg modified release tablet, 120
oxycodone hydrochloride 10 mg modified release tablet, 20
oxycodone hydrochloride 10 mg modified release tablet, 28
oxycodone hydrochloride 10 mg modified release tablet, 60
oxycodone hydrochloride 20 mg capsule

Start Previous Page 11 of 14 Next End


Reference Sets

Australian dialect reference set

Reference set descriptor

Back to Start